State-of-the-Art ReviewFractional Flow Reserve–Based Coronary Artery Bypass Surgery: Current Evidence and Future Directions
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Barbato has received speaker fees from Boston Scientific, Abbott Vascular, and GE. Dr. Oldroyd has served as a consultant for and received speaker fees from Abbott Vascular and Biosensors. Dr. Fremes has received grant support in part by the Bernard S Goldman Chair in Cardiovascular Surgery. Dr. Angiolillo has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has served as a consultant for CeloNova and St. Jude Medical; and has received institutional grant support from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- ∗
Drs. Spadaccio and Glineur contributed equally to this work.